## FIRST YEAR EXAM - SPRING 2013

Monday, May 6th 2013

## NOTES: PLEASE READ CAREFULLY BEFORE BEGINNING EXAM!

- 1. Do not write solutions on the exam; please write your solutions on the paper provided.
- 2. Put the problem number and your assigned code on the top of each page.
- 3. Write only on **one side** of the page (solutions on the reverse side of the page will be ignored).
- 4. Start each problem on a new page.
- 5. It is to your advantage to show your work and explain your answers.

  Do not erase anything–just draw a line through work you do not want graded.
- 6. You have 3 hours to finish the written exam: Questions 1-6 inclusive. Attempt all questions; note that credit is not necessarily equally allocated across questions.
- 7. This is a closed book exam. No notes are permitted.

1. A random string of digits  $X = X_0 X_1 X_2 \dots$  is created sequentially as follows:  $X_0 = 0$  and for  $i \ge 1$ ,

$$X_i = \left\{ egin{array}{ll} X_{i-1} & ext{with probability 0.1} \ X_{i-1} \oplus 1 & ext{with probability 0.9,} \end{array} 
ight.$$

where  $\oplus$  denotes "addition modulo 10", i.e.,  $k \oplus 1 = k+1$  for  $k = 0, 1, \dots, 8$ , but  $9 \oplus 1 = 0$ .

(a) Let  $Z_1$  denote the first  $i \ge 1$  with  $X_i = 0$ . For example, with

$$X = 0123456678890123456789012345567...$$

we will count  $Z_1 = 12$ . Show that  $E(Z_1) = 10$ .

- (b) Suppose the sequential construction is carried on until '0' appears for the 41st time (i.e., 40th reappearance after the initial '0'). Prove that with probability one the string terminates with a finite length.
- (c) Under the stopping rule of part (b), let  $X = X_0 X_1 \dots X_M$  be the full string, with  $X_M$  the 41st '0'. Clearly, M is a random integer and the smallest value it can realize is 40 (when X is a string of 41 '0's). Is P(M > 440) > 0.5? Justify.

2. Skyler selects a random sample of zartylblats and tests each for strength by dropping it on the floor to see if it breaks. Denote by  $\theta$  the probability that a dropped zartylblat will break; and assume independence for the sample.

In the sample of size n = 10, Skyler observed X = 8 broken and 2 unbroken zartylblats.

- (a) What is the likelihood function for  $\theta$  in this problem?
- (b) Skyler announces that her **posterior** distribution for  $\theta$  has density function

$$\pi(\theta \mid X = 8) = c\theta^{10}(1 - \theta)^6, \quad 0 < \theta < 1$$

where  $c = \Gamma(18)/\{\Gamma(11)\Gamma(7)\} = 136136$ . What was Skyler's *prior* distribution? Give the answer as either a density function (correctly normalized if possible) or give the name and the value(s) of any parameter(s).

- (c) Blake has a different prior distribution— she believes that  $\theta$  can take only one of two different values, 1/3 and 2/3, each with prior probability 1/2. With the same data, what is Blake's *posterior* distribution for  $\theta$ ?
- (d) Alex wants to find the (frequentist) *P*-value for a test of the hypothesis  $H_0: \theta = 1/2$  against the one-sided alternative  $H_1: \theta < 1/2$ , with the same data.

Which of the following *is* that *P*-value?

a. 
$$P[X \ge 8 \mid \theta = 1/2]$$
 b.  $P[|X - 5| \ge 3 \mid \theta = 1/2]$  c.  $P[X \le 8 \mid \theta = 1/2]$  d.  $P[\theta < 1/2 \mid X = 8]$  e.  $P[\theta \ne 1/2 \mid X = 8]$  f.  $P[X = 8 \mid \theta < 1/2]$ 

One of the following is the correct numerical value of *P*. Report the correct value and tell how you knew (or how you eliminated the others). If you're unsure, explain. You should not need a calculator or table.

a. 
$$P = 0.000$$
 b.  $P = 0.011$  c.  $P = 0.500$  d.  $P = 0.800$  e.  $P = 0.989$  f.  $P = 1.000$ 

3. Toxicologists want to assess whether two treatment groups differ in the expected number of tumors per animal. There are  $n_1$  animals in treatment group 1 and  $n_2 = n_1$  animals in treatment group 2. Animals are exposed at the beginning of the experiment and at the end the number of tumors is counted so that a count  $y_i \in \{0,1,2,\ldots\}$  is recorded for each animal. Based on previous studies, scientists claim that the Poisson assumption is warranted.

Question: Let the null hypothesis correspond to equivalence between the two groups and the alternative to any difference in the expected tumor counts per animal. Calculate the Bayes factor in favor of the alternative hypothesis under conjugate Ga(1,1) priors, expressed only in terms of the number of animals  $n = n_1 + n_2$  and the total number of tumors on all animals.

- 4. (a) Two scalar random quantities x,z have a joint distribution with complete conditionals  $(x|z) \sim N(x|\phi z,v)$  and  $(z|x) \sim N(z|\phi x,v)$  for some known, positive parameter  $\phi \in (-1,1)$  and where  $v=s(1-\phi^2)$  for some s>0.
  - i. What are the margins p(x) and p(z)? Show your reasoning.
  - ii. What is the joint distribution of (x, z)
  - iii. What is the precision matrix of the joint distribution of (x, z)?
  - (b) A third random quantity y is conditionally distributed as  $(y|x) \sim N(y|x, w)$  for some known w > 0. Also, given x, y is conditionally independent of z.
    - i. What is the joint distribution of (y, x, z)
    - ii. What is E(x|y)?
    - iii. What is E(z|y,x)?
    - iv. What is E(z|y)?

5. Suppose we have observations  $Y_{pc}$  for p = 1, ..., P, a sequence of peptide locations, and c = 1, 2 corresponding to two experimental conditions. To assess existence of a change point at a given location  $p^*$  (one of the P locations), the following model is assumed on these observations:

$$Y_{p1} \sim N(\mu_p, \sigma^2), \ p = 1, ..., P$$
  
 $Y_{p2} \sim N(\mu_p, \sigma^2), \ p = 1, ..., P; \ p \neq p^*$   
 $Y_{p^*2} \sim N(\mu^*, \sigma^2),$ 

with the observations being conditionally independent within and across treatments given model parameters  $\mu_1, \ldots, \mu_P$ ,  $\mu^*$  and  $\sigma^2$ . Let  $\Delta = (\mu^* - \mu_{p^*})/2$ ,  $\bar{\mu}_{p^*} = (\mu^* + \mu_{p^*})/2$  and  $\bar{\mu}_p = \mu_p$  for  $p \neq p^*$ .

- (a) Find the distributions of  $D_p = (Y_{p1} Y_{p2})/2$  and  $M_p = (Y_{p1} + Y_{p2})/2$  for p = 1, ..., P.
- (b) Are the vectors  $D = (D_1, ..., D_P)^T$  and  $M = (M_1, ..., M_P)^T$  independent of each other given  $\Delta$ ,  $\bar{\mu} = (\bar{\mu}_1, ..., \bar{\mu}_P)^T$  and  $\sigma^2$ ?
- (c) Find the MLE of  $\sigma^2$  and simplify it to a function of *D* alone.
- (d) Find the MLE  $\hat{\Delta}$  of  $\Delta$  and the standard error  $SE_{\hat{\Delta}}$  of  $\hat{\Delta}$ .
- (e) What is the distribution of  $(\hat{\Delta} \Delta)/SE_{\hat{\Lambda}}$ ?

- 6. Suppose  $X_i|n_i, p \sim Bin(n_i, p), i = 1, 2, ..., I$ , conditionally independent with the  $n_i$  and p unknown. Suppose we adopt a  $Be(\alpha, \beta)$  prior for p. Suppose, a priori, the  $n_i$  are independent and consider two improper priors for them:
  - (I)  $\pi(n_i) \propto 1$ , a discrete uniform
  - **(II)**  $\pi(n_i) \propto 1/n_i$ , a "scale" or geometric prior

We can immediately write down the joint posterior for  $\{n_i\}$ , p up to proportionality and, for each of these priors, we can marginalize over the  $n_i$  to obtain the marginal posterior distribution for p.

- (a) Show that, under prior (I), the posterior distribution for p is improper if  $\alpha < I$ .
- (b) Show that, under prior (II), if all of the  $x_i > 0$ , the posterior distribution on p is the same as the prior.
- (c) Without doing any calculations, speculate on what the story would be if we considered the prior,  $\pi(n_i) \propto 1/n_i^2$ .

## Take Home Data Analysis Problem

Right Heart Catheterization (RHC) is a procedure for directly measuring how well the heart is pumping blood to the lungs. RHC is often applied to critically ill patients for directing immediate and subsequent treatment. However, administering RHC may cause serious complications, though the risks are usually small. There is some debate whether the use of RHC actually leads to improved treatment.

The data set "rhc\_study" (more information below) contains data on 3824 hospitalized adult patients at five medical centers in the U.S. The variable rhc (column 1) indicates whether RHC was applied within 24 hours of admission (TRUE/FALSE). Each patient was followed up with some treatment procedures that may have been influenced by the RHC result if it was performed on the patient. The outcome variable is surv30 (column 54) which is a prognosis score describing the probability of survival at 30 days after completion of treatment. The prognosis score derivation is a standardized procedure and is calculated by following the same protocol for all patients at all centers. Based on information from a panel of experts, a set of 52 variables were identified that are potentially related to both the decision to use RHC and the outcome surv30.

An accompanying data set "rhc\_new" contains information on 1911 "new" patients admitted to the same five centers for serious health complications similar to the patients in rhc\_study. These new patients are to be treated upon, with or without RHC being used to determine the choice of treatment. The data set rhc\_new has the same 54 columns as rhc\_study, but its column 1 and column 54 contain only NA's.

Present a three page (maximum) report addressing the question: Should RHC be performed to assist treatment choices for new patients in order to maximize their individual prognosis scores? Your report should discuss all relevant aspects of your analysis (exploratory, modeling and validation) with graphical and numerical summaries that are important for communicating results. The report should be written so that doctors could understand and apply the findings while making RHC recommendation for future care. While you may include code and other plots in the supplemental appendix, you should not assume that graders will read beyond the main report; all relevant material should be within the three page limit.

You can access the two data sets in either tab delimited format (readable to R) or comma delimited 'csv' format (readable to Excel and R) from http://www.stat.duke.edu/~st118/fye13/takehome/. Details on all 54 variables are given on the next page.

Submit your report electronically to Karen Herndon by email (karen@stat.duke.edu). Your report file should be named fye13\_codename.pdf. Your report should not contain your name or any other identifier. It MUST include your assigned code name.

```
RHC applied (TRUE / FALSE)
            Age (years)
      age
            Male/Female
      sex
            black/white/other
     race
     edu
            Education (years)
            > $50k/ $11-$25k/ $25-$50k/ Under $11k
  income
            Insurance (Medicaid/Medicare Medicare & Medicaid/No insurance/Private/Private & Medicare)
 ninsclas
     cat1
            Primary
                      disease
                                category
                                           (ARF/CHF/Cirrhosis/Colon Cancer/Coma/COPD/Lung
                                                                                                     Cancer
            /MOSF+Malignancy/MOSF+Sepsis)
     cat2
            Secondary disease category (Cirrhosis/Colon Cancer/Coma/Lung Cancer/MOSF+Malignancy/
            MOSF+Sepsis/None)
     resp
            Respiratory diagnosis (Yes/No)
            Cardiovascular diagnosis (Yes/No)
     card
    neuro
            Neurological diagnosis (Yes/No)
            Gastrointestinal diagnosis (Yes/No)
    gastr
            Renal diagnosis (Yes/No)
    renal
            Metabolic diagnosis (Yes/No)
    meta
    hema
            Hematological diagnosis (Yes/No)
     seps
            Sepsis diagnosis (Yes/No)
            Trauma diagnosis (Yes/No)
  trauma
    ortho
            Orthopedic diagnosis (Yes/No)
das2d3pc
            DASI - Duke Activity Status Index
     dnr1
            Do Not Resuscitate status on day 1 (Yes/No)
       ca
            Metastatic cancer (Yes/No)
surv2md1
            Estimate of prob. of surviving 2 months
            APACHE score
     aps1
            Glasgow coma score
  scoma1
  wtkilo1
            Weight (Kg)
   temp1
            Temperature (Celsius)
meanbp1
            Mean Blood Pressure
    resp1
            Respiratory Rate
     hrt1
            Heart Rate
    pafi1
            PaO2=FI02 ratio
  paco21
            PaCO2
     ph1
            PH
   wblc1
            WBC
   hema1
            Hematocrit
     sod1
            Sodium
     pot1
            Potassium
    crea1
            Creatinine
            Bilirubin
     bili1
     alb1
            Albumin
 cardiohx
            Cardiovascular symptoms (TRUE/FALSE)
    chfhx
            Congestive Heart Failure (TRUE/FALSE)
dementhx
            Dementia, stroke or cerebral infarct, Parkinsons disease (TRUE/FALSE)
 psychhx
            Psychiatric history, active psychosis or severe depression (TRUE/FALSE)
chrpulhx
            Chronic pulmonary disease, severe pulmonary disease renalhx (TRUE/FALSE)
  renalhx
            Chronic renal disease, chronic hemodialysis or peritoneal dialysis (TRUE/FALSE)
  liverhx
            Cirrhosis, hepatic failure (TRUE/FALSE)
 gibledhx
            Upper GI bleeding (TRUE/FALSE)
 malighx
            Solid tumor, metastatic disease, chronic leukemia=myeloma, acute leukemia, lymphoma (TRUE/FALSE)
immunhx
            Immunosuppression, organ transplant, HIV, Diabetes Mellitus, Connective Tissue Disease (TRUE/FALSE)
  transhx
            Transfer ( > 24 hours) from another hospital (TRUE/FALSE)
   amihx
            Definite myocardial infarction (TRUE/FALSE)
     wt0
            Missing weight recorded as 0 (TRUE/FALSE)
```

Outcome: prognosis of chance of surviving more than 30 days

surv30

## **Take-home Applied Exam**

- Keep your answer concise and to the point.
- Present your results in a three page (maximum) report addressing the primary questions posed.
- Your report should discuss all relevant aspects of your analysis (exploratory and modeling) with graphical and numerical summaries that are important for communicating results.
- You may include code and other plots in a supplemental appendix; BUT, you should not assume that graders will read beyond the main report; all relevant material should be within the three page limit.
- You may use all notes, books, software etc from courses and studies to date, and build on your cumulated experience in applied modeling and data analysis.
- BUT- you are also bound by this honor pledge and must sign below to confirm this:
  - I confirm that this Take-home Exam submission is my work alone.
  - I have not consulted at all with any other students, whether they are taking the exam or not.
  - I have not copied nor adapted the work of others, nor provided help or advice to others on this exam.
  - I have not sought out or used any external sources (past student projects, publications, web sites, etc) that explicitly address any aspects of the specific data set and applied problem here. In particular, I have not used web searches to find previous references to the data and earlier analyses of this specific data set and problem, of any kind.
- Sign below and hand this in with your solution.

Name:				
Signatu	re:			
Date:	May 8th 2013			

Distribution	Notation	$f(x) = \mathbf{pdt} (\mathbf{pmt})$	Support	Mean	Variance	
Beta	Be(a,b)	$f(x) = \frac{\Gamma(a+b)}{\Gamma(a)\Gamma(b)} x^{a-1} (1-x)^{b-1}$	$x \in (0,1)$	$\frac{a}{a+b}$	$\frac{ab}{(a+b)^2(a+b+1)}$	
Bernoulli	Bern(p)		$x \in \{0, 1\}$	d	bd	(q=1-p)
Binomial	Bin(n, p)	$f(x) = \binom{n}{x} p^x q^{(n-x)}$	$x \in \{0, \cdots, n\}$		bdu	(q=1-p)
Chi-square	$\chi^2( u)$	$f(x) = \frac{1}{2^{\nu/2}\Gamma(\nu/2)} x^{\nu/2-1} e^{-x/2}$	$x\in {\rm I\!R}_+$	7	$2\nu$	
Exponential	$Ex(\lambda)$	$f(x) = \lambda e^{-\lambda x}$	$x\in {\rm I\!R}_+$	$1/\lambda$	$1/\lambda^2$	
Gamma	$Ga(\nu,\lambda)$	$f(x) = \frac{\lambda^{\nu}}{\Gamma(\nu)} x^{\nu - 1} e^{-\lambda x}$	$x\in {\rm I\!R}_+$	$\nu/\lambda$	$\nu/\lambda^2$	
Geometric	Geo(p)		$x\in \mathbb{Z}_{+}$	d/b	$q/p^2$	(q=1-p)
		$f(y) = p  q^{y-1}$	$y \in \{1,\}$	1/p	$q/p^2$	(y = x + 1)
HyperGeo.	HG(n, M, N)	$f(x) = \frac{\binom{M}{x} \binom{N-M}{n-x}}{\binom{N}{x}}$	$x \in 0, \cdots, n$	ди	$n p \left(1 - p\right) \frac{N - n}{N - 1}$	$(\frac{M}{N}=d)$
Logistic	$Lo(\mu, \beta)$	$f(x) = \frac{e^{-(x-\mu)/\beta}}{\beta_{11+\rho^{-(x-\mu)/\beta_{12}}}}$	$x\in { m I\!R}$	н	$\pi^2 \beta^2/3$	
Log Normal	$LN(\mu,\sigma^2)$		$x\in {\rm I\!R}_+$	$e^{\mu+\sigma^2/2}$	$e^{2\mu+\sigma^2}\big(e^{\sigma^2}\!\!-\!1\big)$	
Neg. Binom.	$NB(\alpha, p)$	$f(x) = \binom{x+\alpha-1}{x} p^{\alpha} q^{x}$	$x\in \mathbb{Z}_{+}$	d/bw	$\alpha q / p^2$	(q=1-p)
		$f(y) = \binom{y-1}{y-\alpha} p^{\alpha} q^{y-\alpha}$	$y \in \{\alpha,\}$	$\alpha/p$	$\alpha q/p^2$	$(y = x + \alpha)$
Normal	$N(\mu,\sigma^2)$		$x\in { m I\!R}$	н	$\sigma^2$	
Pareto	$Pa(\alpha,\epsilon)$		$x\in(\epsilon,\infty)$	$\frac{\epsilon  \alpha}{\alpha - 1}$	$\frac{\epsilon^2 \alpha}{(\alpha - 1)^2 (\alpha - 2)}$	
Poisson	$Poi(\lambda)$	$f(x) = \frac{\lambda^x}{x!}e^{-\lambda}$	$x\in \mathbb{Z}_+$	7	\ \ \	
${\bf Snedecor}\ F$	$F(\nu_1,\nu_2)$	$f(x) = \frac{\Gamma(\frac{\nu_1 + \nu_2}{2})(\nu_1/\nu_2)^{\nu_1/2}}{\Gamma(\frac{\nu_1}{2})\Gamma(\frac{\nu_2}{2})} \times$	$x\in \mathbb{R}_+$	$\frac{v_2}{v_2-2}$	$\left(\frac{\nu_2}{\nu_2 - 2}\right)^2 \frac{2(\nu_1 + \nu_2 - 2)}{\nu_1(\nu_2 - 4)}$	$\frac{+\nu_2-2)}{\nu_2-4)}$
		$x^{\frac{v_1-2}{2}} \left[1+\frac{v_1}{v_2}x\right]^{-\frac{v_1+v_2}{2}}$	<u>. 7</u>			
Student t	t( u)	$f(x) = \frac{\Gamma(\frac{\nu+1}{2})}{\Gamma(\frac{\nu}{2})\sqrt{\pi\nu}} [1 + x^2/\nu]^{-(\nu+1)/2}$	$x\in \mathbb{R}$	0	v/(v-2)	
Uniform	U(a,b)		$x \in (a, b)$	$\frac{a+b}{2}$	$\frac{(b-a)^2}{12}$	
Weibull	Wei(lpha,eta)	$f(x) = \alpha \beta  x^{\alpha - 1}  e^{-\beta  x^{\alpha}}$	$x\in {\rm I\!R}_+$	$\frac{\Gamma(1{+}\alpha^{-1})}{\beta^{1/\alpha}}$	$\frac{\Gamma(1+2/\alpha)-\Gamma^2(1+1/\alpha)}{\beta^{2/\alpha}}$	